Mirum Pharmaceuticals, Inc. MIRM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $569.61M+9.3% | $521.31M+10.5% | $471.79M+9.9% | $429.16M+13.2% | $379.25M+12.6% | ||
| $238.04M+31.4% | $181.18M+4.1% | $174.1M+6.9% | $162.85M+9.0% | $149.45M+6.3% | ||
| $295.65M+15.0% | $257.03M+7.2% | $239.73M+5.0% | $228.37M+6.6% | $214.29M+6.0% | ||
| $1.37B+151% | $543.45M+5.8% | $513.59M+5.6% | $486.24M+6.7% | $455.57M+7.3% | ||
| $1.37B+151% | $543.45M+5.8% | $513.59M+5.6% | $486.24M+6.7% | $455.57M+7.3% | ||
| -$796.42M-3,498% | -$22.14M+47.0% | -$41.79M+26.8% | -$57.08M+25.2% | -$76.32M+12.9% | ||
| -139.8%-136pp | -4.2%+4.6pp | -8.9%+4.4pp | -13.3%+6.8pp | -20.1%+5.9pp | ||
| $14.41M+0.1% | $14.39M+0.1% | $14.37M+0.1% | $14.35M+0.1% | $14.33M+0.1% | ||
| $13.11M+3.0% | $12.73M+1.7% | $12.51M-1.7% | $12.73M-3.4% | $13.18M-4.4% | ||
| $481K-81.4% | $2.59M-8.2% | $2.82M+111% | $1.34M-14.5% | $1.56M+28.9% | ||
| -$797.46M-3,622% | -$21.43M+47.5% | -$40.83M+28.8% | -$57.36M+24.4% | -$75.91M+12.7% | ||
| $1.38M-28.6% | $1.94M— | —— | —— | —— | ||
| -$798.84M-3,319% | -$23.36M+43.6% | -$41.42M+29.3% | -$58.56M+24.3% | -$77.34M+12.1% | ||
| -140.2%-136pp | -4.5%+4.3pp | -8.8%+4.9pp | -13.6%+6.7pp | -20.4%+5.7pp | ||
| -$13.62-2,680% | -$0.49+43.0% | -$0.86+28.9% | -$1.21+24.8% | -$1.61+13.0% | ||
| -$13.61-2,735% | -$0.48+43.5% | -$0.85+29.8% | -$1.21+24.8% | -$1.61+13.0% | ||
| 215.8M+4.8% | 205.8M+1.3% | 203.1M+4.7% | 193.9M+1.3% | 191.4M+1.0% | ||
| 209.4M+5.0% | 199.5M+1.4% | 196.8M+1.5% | 193.9M+1.3% | 191.4M+1.0% | ||
| $106.03M+5.8% | $100.24M+5.8% | $94.76M+5.3% | $90.03M+3.7% | $86.83M+6.4% | ||
| —— | —— | —— | —— | —— | ||
| $481K-81.4% | $2.59M-8.2% | $2.82M+111% | $1.34M-14.5% | $1.56M+28.9% | ||
| $238.04M+31.4% | $181.18M+4.1% | $174.1M+6.9% | $162.85M+9.0% | $149.45M+6.3% | ||
| $569.61M+9.3% | $521.31M+10.5% | $471.79M+9.9% | $429.16M+13.2% | $379.25M+12.6% | ||
| -$796.42M-3,498% | -$22.14M+47.0% | -$41.79M+26.8% | -$57.08M+25.2% | -$76.32M+12.9% | ||
| -$771.35M-36,692% | $2.11M+112% | -$17.57M+46.5% | -$32.86M+37.2% | -$52.3M+18.2% | ||
| -$771.35M-36,692% | $2.11M+112% | -$17.57M+46.5% | -$32.86M+37.2% | -$52.3M+18.2% | ||
| -135.4%-136pp | 0.4%+4.1pp | -3.7%+3.9pp | -7.7%+6.1pp | -13.8%+5.2pp | ||
| -$796.42M-3,498% | -$22.14M+47.0% | -$41.79M+26.8% | -$57.08M+25.2% | -$76.32M+12.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s revenue?
- Mirum Pharmaceuticals, Inc. (MIRM) generated $569.6M in revenue over the trailing twelve months, up 50.2% year over year.
- Is Mirum Pharmaceuticals, Inc. profitable?
- Mirum Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $798.8M over the trailing twelve months, a -140.2% net margin.
- What is Mirum Pharmaceuticals, Inc.'s earnings per share?
- Mirum Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-13.62.
- Where does Mirum Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
